News

As part of the partnership, Summit will manufacture a multidose nasal spray presentation of AdCOVID, Altimmune’s intranasal COVID-19 vaccine candidate. AdCOVID is currently being evaluated in a phase 1 clinical trial of healthy adult volunteers between the ages of 18 and 55.

The report details the findings of surveys taken by more than 900 healthcare providers, school leaders, community health workers and their clients, and community members in Kentucky during the summer and fall of 2020.

UKNow sat down with University of Kentucky College of Public Health Dean Donna Arnett and Marc Kiviniemi, chair of the Department of Health, Behavior & Society in the College of Public Health, to get some answers on how COVID-19 will affect us moving forward.

“It is too early to tell if 2020 youth suicide death rates are up — this data takes more than a year to compile. But we’re hearing suicide deaths seem to be down, even if attempts and help-seeking are way up,” Julie Cerel said.

On this episode of "Behind the Blue," Dutch talks about the new vaccines being used to combat the coronavirus, the genetic variations of the virus that are appearing in different parts of the world, her outlook for when we may emerge from the pandemic, and more.

The Phase 3 ENSEMBLE 2 study is a randomized, double-blind, placebo-controlled clinical trial in up to 30,000 adults 18 years old and older. The trial will include people both with and without comorbidities associated with an increased risk for severe COVID-19.

According to the report, as of October, the state had recovered 67% of jobs lost during the first months of the pandemic. But the recovery remains far from complete. Kentucky’s employment was still down 107,600 jobs — or 5.5% — from January 2020.

The Phase 3 randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the safety and efficacy of a single vaccine dose of the Janssen investigational COVID-19 vaccine candidate versus placebo. Approximately 45,000 people participated worldwide. The combined UK, Baptist and Norton site was among the top enrolling sites in the world.

The University of Kentucky Markey Cancer Center is teaming up with the National Comprehensive Cancer Network® (NCCN®), the American Cancer Society (ACS) and other leading cancer organizations across the country to endorse the resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.

"While approved vaccines are able to prevent a COVID reinfection with a high effectiveness rate, it is still early on and we don't know how durable they are going to be in the long run. We also don’t know how effective these vaccines are at preventing asymptomatic spread. These questions are what researchers in my field will be looking at for many years to come."